NCT05907850

Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes

A Randomized Placebo-controlled Trial Investigating the Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Steven Moore · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The aim of this project is to investigate the effects of riboflavin, also known as vitamin B2, on preventing delayed onset muscle soreness (DOMS) in ultramarathon athletes through a randomized placebo-controlled study.

Detailed description

The riboflavin 100 mg capsules will be self-dosed by the participant, one capsule prior to the long stage of the race followed by a second dose at the end of the long stage. Historically, long-stage finish times have ranged between 8 and 24 hours. The placebo will also be dosed as one capsule on the morning of the long stage, prior to the race start, and one capsule at the end of the long stage.

Conditions

• Muscle Soreness

Interventions

Type	Name	Description
DRUG	Riboflavin	Commercially available source of riboflavin capsules
DRUG	Placebo	Placebo capsule compounded to be similar in appearance to the active intervention

Timeline

• Start date: 2023-06-23
• Primary completion: 2024-05-30
• Completion: 2024-05-30
• First posted: 2023-06-18
• Last updated: 2025-04-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study